U.S. Consumer Durables Stock News

Recent share performance snapshot Herbalife (HLF) has drawn fresh attention after a recent share price move, with the stock closing at $16.28. Over the past month, the shares show a 13.1% gain, in contrast with a 5.6% decline over the past 3 months. See our latest analysis for Herbalife. That recent 13.1% 1 month share price return comes after a softer 3 month period and sits alongside a 1 year total shareholder return of 122.4%. This suggests momentum has picked up again, while longer term...

Texas Instruments collaboration puts Lattice’s edge AI focus in the spotlight Lattice Semiconductor (LSCC) has drawn fresh attention after announcing a collaboration with Texas Instruments that links Lattice’s low power FPGA based Holoscan Sensor Bridge with TI sensing technologies for real time edge AI systems. See our latest analysis for Lattice Semiconductor. The Texas Instruments partnership arrives after a strong run in the stock, with a 30 day share price return of 27.3% and a 90 day...

Option Care Health (OPCH) opened 2026 with Q1 revenue of US$1.4b and basic EPS of US$0.29, setting the tone for how the year is starting to shape up after a busy 2025. The company has seen quarterly revenue move from US$1.33b in Q1 2025 to US$1.35b in Q1 2026, while basic EPS shifted from US$0.28 to US$0.29 over the same period, giving you a clean view of how the top and bottom lines are tracking across the year on year comp. With trailing margins softer than a year ago, this latest print...

If you are wondering whether Teradata is attractively priced or looking stretched at its current levels, you will want to understand what the valuation numbers are actually saying. The stock last closed at US$27.96, with returns of 5.8% over the past week, 10.8% over the past month, a 5.8% decline year to date, and 26.7% over the last year, alongside weaker 3 year and 5 year returns of 37.2% and 31.0% respectively. These mixed returns have kept Teradata on the radar for investors who pay...

Recent share performance and current scale Abercrombie & Fitch (ANF) shares have pulled back recently, with the price at US$84.54 after a 1 day return of a 0.9% decline and a past month return of a 10.3% decline. Over the past 3 months the stock shows a 13.4% decline, while the 1 year total return is 19.4%. Over a longer period, total returns are 2.72x over 3 years and about 1.07x over 5 years. The company now carries a market value of about US$3.8b and reported revenue of US$5,266.292m with...

In April 2026, Park National Corporation reported first-quarter 2026 results showing higher net interest income of US$125.78 million but slightly lower net income of US$41.69 million and earnings per share, alongside a quarterly dividend declaration of US$1.10 per share. The quarter also featured a rise in net charge-offs to US$2.63 million from US$592,000 a year earlier, putting asset quality trends in sharper focus for investors. We’ll now look at how the mix of rising net interest income...

In April 2026, Agree Realty Corporation completed roughly US$1.00 billion of follow-on common equity offerings and filed an additional US$1.75 billion at-the-market equity program alongside a new universal shelf registration covering common and preferred stock, depositary shares, warrants, and debt securities. This combination of fresh equity capital and expanded shelf capacity signals that Agree Realty is preparing for a potentially larger, more flexible funding toolkit to support its...

Coupang, Inc. recently drew attention as analysts shifted expectations for its March 2026 quarter toward a loss despite higher year-over-year revenues, ahead of its now-past May 5, 2026 earnings release. This mix of projected revenue growth, anticipated earnings pressure, and debate over a possible earnings beat has intensified focus on Coupang’s underlying performance drivers and risk profile. We’ll now explore how the uncertainty around a projected loss despite revenue growth might...

In recent weeks, lululemon athletica has entered a high-profile proxy fight as founder Dennis “Chip” Wilson filed a definitive proxy statement seeking to elect his own three director nominees and urging shareholders to withhold support from several current board candidates, amid ongoing leadership transition to incoming CEO Heidi O’Neill and recent additions to the board including Esi Eggleston Bracey. The dispute has widened as the company and Wilson trade accusations over brand direction,...

Bullish (BLSH) has drawn attention after its recent trading performance, with a 4.2% move over the past day, a small decline over the past week, and double digit gains over the past month and past 3 months. See our latest analysis for Bullish. That recent 4.21% 1 day share price return comes after a 12.12% 30 day and 30.20% 90 day share price return. This suggests momentum has been building even though the year to date share price return is close to flat. If Bullish has you looking more...

Tronox Holdings (TROX) is back in focus after Truist cut its rating to Sell, citing the risk of softer fiscal Q2 guidance, cost pressures, and an unfavorable geographic mix that may weigh on near term earnings. See our latest analysis for Tronox Holdings. Despite the downgrade, Tronox’s share price has been strong, with a 10.13% 1 month share price return and a 70.46% 3 month share price return. However, the 5 year total shareholder return of a 46.69% loss shows the longer term recovery...

Garmin (NYSE:GRMN) reports record Q1 2026 revenue and operating income, setting new highs for the company. Fitness segment revenue rises 42% in Q1 2026, supported by advanced wearables and recent product launches. Garmin plans around 100 product launches in 2026 across its diversified segments. The company secures multiple new EASA certifications for aviation equipment, expanding its presence in the European market. For investors tracking consumer electronics and aerospace, Garmin sits at...

Why Braze’s new AI tools matter for investors Braze (BRZE) recently rolled out BrazeAI Operator, BrazeAI Agent Console and a revamped Creative Studio with Figma and Canva integrations, a product release that puts AI driven personalization and content workflows at the center of its customer engagement platform. At the same time, the company reaffirmed its guidance and outlined leadership changes, providing several fresh data points for investors to consider when weighing how this evolving AI...

Nuvation Bio recently reported that taletrectinib (IBTROZI) was added to the NCCN Clinical Practice Guidelines for CNS cancers as a systemic therapy option for ROS1-positive non-small cell lung cancer patients with brain metastases, following strong long-term efficacy and safety data from the TRUST program presented at the 2026 AACR meeting. This recognition not only supports broader clinical use in a difficult-to-treat subset but also highlights IBTROZI’s differentiated intracranial...

FuboTV (FUBO) is drawing fresh attention as its platform carries high-interest live sports, including Seattle Mariners MLB games and the Portland Fire’s WNBA debut. This highlights the service’s positioning with dedicated sports viewers. See our latest analysis for FuboTV. That interest in live sports is arriving at a time when FuboTV’s share price has moved sharply in both directions, with a 1 month share price return of 50.22% contrasting with a 1 year total shareholder return decline of...

Banco Latinoamericano de Comercio Exterior S. A. gained shareholder approval at its recent Annual Shareholders' Meeting to change its legal name to Bladex Inc. The rebranding will shift the company’s official identity while it continues to trade on the NYSE under ticker NYSE:BLX. The name change is expected to influence how the bank presents itself to clients, investors, and counterparties across Latin America and beyond. The rebrand to Bladex Inc. comes at a time when NYSE:BLX shares are...

NovoCure (NasdaqGS:NVCR) received FDA approval for Optune Pax for locally advanced pancreatic cancer and has started its U.S. commercial launch. The new therapy has seen early adoption and payer coverage in the U.S., expanding NovoCure's reach beyond its original focus in glioblastoma. Pivotal Phase 3 data from the TRIDENT trial in newly diagnosed glioblastoma are expected later this year. NovoCure focuses on tumor treating fields therapy, a medical technology designed to disrupt cancer...

Hut 8 (HUT) has recently drawn attention after its share price moved sharply over the past month, with a one-month return of 62.5% and a three-month return of 37.9%. See our latest analysis for Hut 8. At a share price of $76.98, Hut 8 has combined a sharp 30 day share price return and solid year to date move with a very large 1 year total shareholder return. This suggests that recent gains may reflect shifting expectations around its energy infrastructure and compute operations rather than a...

Why NCR Atleos (NATL) is on investors’ radar today NCR Atleos (NATL) has attracted fresh attention after recent trading left the stock at a last close of $44.52, with returns of 0.3% over the past day and about 19% over the past 3 months. For readers tracking company level fundamentals, NCR Atleos reports annual revenue of $4.354b and net income of $162.0m, alongside a reported value score of 1 that may prompt closer comparison with other financial technology names. See our latest analysis...

For investors considering whether Constellium at around US$32.01 is offering good value or getting ahead of itself, this article examines what the current price might be implying about the stock. The share price has recently been active, with returns of 2.0% over 7 days, 17.2% over 30 days, 61.9% year to date and 187.3% over the past year, which can change how the market views both opportunity and risk. Recent news flow around Constellium has focused on the broader materials sector and...

Ocular Therapeutix recently enrolled the first patient in its SOL-X long-term extension trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration, a 36‑month open-label study designed to assess long-term safety, efficacy, and disease-modifying potential following completion of the SOL-1 or SOL-R trials. This extension study is intended to test whether earlier and sustained AXPAXLI therapy can reduce fibrosis, macular atrophy, and treatment burden compared with pulsatile anti-VEGF...

MasTec (MTZ) opened Q1 2026 with revenue of about US$3.8b and basic EPS of US$0.78, setting the tone for how the rest of the year may shape up on both the top and bottom line. Over the past six reported quarters, revenue has moved from US$3.4b in Q4 2024 to just under US$4.0b in Q3 2025 before landing at US$3.8b in the latest quarter. Quarterly basic EPS has ranged from US$0.13 in Q1 2025 to US$2.07 in Q3 2025 and stands at US$0.78 in Q1 2026. With trailing twelve month net income of...

Antero Resources reported past first-quarter 2026 results with revenue of US$1,945.13 million, net income of US$535.22 million, and record production of 3,852 MMcfe/d, alongside sharply lower property and equipment impairment charges. The company also reaffirmed its 2026 production guidance while highlighting ahead-of-schedule integration of the HG acquisition, which is already contributing to higher volumes and operational efficiencies. We’ll now examine how this record quarterly...

Recently, MP Materials announced plans for a US$1.25 billion rare earth magnet facility in Northlake, Texas, while media coverage highlighted its public‑private partnership with the U.S. Department of Defense, including a 10‑year price floor on NdPr oxide and an equity stake of about 15%. This combination of long‑term government backing, critical mineral positioning, and downstream expansion into magnets and supply agreements with Apple and General Motors underscores MP Materials’ role at...